Key Inclusion Criteria:  Written informed consent Male or female, aged ≥18 years and ≤75 years Histologically or cytologically documented lung adenocarcinoma with completely resectable disease (Stage II-IIIB N2, according to the 8th edition of the IASLC Staging Manual in Thoracic Oncology) Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by an MDT evaluation A tumor which harbors either Ex19del or L858R EGFR-TKI-sensitizing mutations, either alone ECOG PS 0/1 at enrollment, with no deterioration over the previous 2 weeks prior to baseline or day of first dosing  Adequate organ and marrow function as defined by:  Hemoglobin: ≥9.0 g/dL Absolute neutrophil count: ≥1.5 × 109/l Platelet count: ≥100 × 109/l Serum bilirubin: ≤1.5 ULN ALT and AST: ≤2.5 × ULN Creatinine clearance: ≥60 ml/min Life expectancy of 6 months prior to randomization  Exclusion Criteria:  Prior treatment with systemic anti-cancer treatment for NSCLC, EGFR-TKI treatment or pre-operative radiotherapy EGFR-TKI-sensitizing mutations with T790M Mixed small cell and non-small-cell lung cancer histology T4 tumors infiltrating the aorta, esophagus and/or heart Bulky N2 disease Candidates for segmentectomies or wedge resections only Medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment or any evidence of clinically active ILD Severe or uncontrolled systemic diseases/active infections, history of allogeneic organ transplantation, history of primary immunodeficiency, history of another primary malignancy